Product image of Ibandronic Acid Mylan (Ibandronic Acid) supplied by GNH India

Ibandronic Acid Mylan

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronic Acid Mylan (Ibandronic Acid)

Ibandronic acid, the active ingredient in Ibandronic Acid Mylan, is a bisphosphonate presented as an oral tablet for oral use. It is indicated for osteoporosis in postmenopausal women, prevention of fractures, and Paget's disease of bone.
GNH India supplies Ibandronic Acid Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Generics [uk] Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibandronic Acid Mylan is a bisphosphonate that acts on bone remodeling pathways to treat several skeletal disorders.

  • Osteoporosis in postmenopausal women: reduces the risk of vertebral and non‑vertebral fractures.
  • Prevention of fractures in osteoporosis: improves bone mineral density and lowers overall fracture incidence.
  • Paget's disease of bone: normalizes bone turnover and alleviates bone pain.

How It Works

  • Ibandronic acid binds avidly to hydroxyapatite crystals in bone, becoming incorporated into the mineral matrix. When osteoclasts resorb bone containing the drug, ibandronate is released intracellularly, inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway. This disruption induces osteoclast apoptosis, thereby decreasing bone resorption and stabilizing bone mass.

Side Effects

Ibandronic Acid Mylan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, dyspepsia, abdominal pain.
  • Musculoskeletal pain: bone, joint or muscle discomfort.
  • Headache: mild to moderate intensity.
  • Transient flu‑like symptoms: fever, chills, myalgia.
  • Esophageal irritation: heartburn or reflux.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: painful exposed bone in the oral cavity.
  • Atypical femur fracture: low‑energy fracture of the subtrochanteric region.
  • Severe esophagitis: ulceration or erosive lesions.
  • Acute phase reaction: fever, arthralgia, rash.
  • Renal impairment: acute kidney injury, especially with dehydration.
  • Hypersensitivity reactions: rash, angioedema, anaphylaxis.

Precautions & Warnings

Before prescribing Ibandronic Acid Mylan, clinicians should evaluate several safety considerations.

  • Assess renal function: confirm adequate creatinine clearance prior to initiation.
  • Ensure adequate calcium/vitamin D: supplement to prevent hypocalcemia.
  • Take with water: swallow tablet with a full glass of water and remain upright for at least 30 minutes.
  • Avoid concomitant oral bisphosphonates: do not use other bisphosphonates simultaneously.
  • Review esophageal disorders: contraindicated in active esophageal disease.
  • Store at room temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Ibandronic Acid Mylan can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Calcium supplements: may markedly reduce ibandronate absorption if taken together.
  • Antacids containing aluminum or magnesium: interfere with bioavailability.
  • Concomitant NSAIDs: increase risk of gastrointestinal irritation.
  • Systemic corticosteroids: may exacerbate bone loss.
  • Renal toxic drugs (e.g., aminoglycosides): heighten risk of renal impairment.

Moderate Interactions (Monitor Closely)

  • Vitamin D analogues: monitor serum calcium levels.
  • Warfarin: may affect INR; regular coagulation monitoring recommended.
  • Thiazide diuretics: risk of hypercalcemia; check electrolytes.
  • Hormone replacement therapy: may alter bone turnover; observe response.
  • Proton‑pump inhibitors: may increase esophageal irritation; assess symptoms.

Frequently Asked Questions

Ibandronic Acid Mylan is prescribed to treat osteoporosis in postmenopausal women, to help prevent fractures in patients with established osteoporosis, and to manage Paget's disease of bone by normalizing abnormal bone remodeling.

Ibandronic acid binds to bone mineral surfaces and, when osteoclasts attempt to resorb that bone, it inhibits the enzyme farnesyl pyrophosphate synthase. This blocks a key step in the mevalonate pathway, leading to osteoclast apoptosis and a reduction in bone resorption.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and this decision should be made by a qualified healthcare professional.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ibandronic acid is a third‑generation bisphosphonate with a longer dosing interval (often monthly) compared with alendronate or risedronate, which are typically taken weekly. Its potency in inhibiting bone resorption is comparable, but individual response and tolerability may vary.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight to maintain stability throughout the shelf life.

The medication is taken orally as a tablet. Patients should swallow the tablet with a full glass of water on an empty stomach, remain upright for at least 30 minutes, and avoid eating or drinking anything else during that time.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe esophagitis, acute renal impairment, and hypersensitivity reactions such as anaphylaxis. Patients should be educated to report any persistent oral pain, unusual thigh pain, or signs of infection promptly.

Patients with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders, hypersensitivity to ibandronate or other bisphosphonates, and those who are unable to follow the required administration instructions should avoid using this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT